Zileuton

• CAT Number: A000793
• CAS Number: 111406-87-2
• Molecular Formula: C11H12N2O2S
• Molecular Weight: 236.30
• Purity: ≥95%
• Synonyms: 111406-87-2; Zyflo; Leutrol; Zileutonum; Zyflo CR
• Target: 5-Lipoxygenase
• Solubility: >13.3mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea
• InChI: InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)
• InChIKey: MWLSOWXNZPKENC-UHFFFAOYSA-N
• SMILES: CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O

Zileuton（Cat No.:A000793）is a potent inhibitor of 5-lipoxygenase (5-LOX), an enzyme critical in the biosynthesis of leukotrienes, which are inflammatory mediators involved in asthma and allergic reactions. By blocking leukotriene production, zileuton reduces airway inflammation, bronchoconstriction, and other asthma-related symptoms. It is used clinically to manage chronic asthma, offering a non-steroidal option for controlling inflammation. Zileuton’s ability to target the 5-LOX pathway makes it a key therapeutic agent in treating asthma and other inflammatory conditions where leukotrienes play a significant role.

Reference

1: Li DD, Xie H, Du YF, Long Y, Reed MN, Hu M, Suppiramaniam V, Hong H, Tang SS.
Antidepressant-like effect of zileuton is accompanied by hippocampal
neuroinflammation reduction and CREB/BDNF upregulation in
lipopolysaccharide-challenged mice. J Affect Disord. 2017 Nov 13;227:672-680.
doi: 10.1016/j.jad.2017.11.047. [Epub ahead of print] PubMed PMID: 29174741.

2: Saul D, Ninkovic M, Komrakova M, Wolff L, Gasimov T, Menger B, Hoffmann DB,
Rohde V, Sehmisch S. Effect of zileuton on osteoporotic bone and its healing,
expression of bone and brain genes in rats. J Appl Physiol (1985). 2017 Aug
31:jap.01126.2016. doi: 10.1152/japplphysiol.01126.2016. [Epub ahead of print]
PubMed PMID: 28860177.

3: Bouchette D, Pellegrini MV. Zileuton. 2017 Oct 9. StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2017 Jun-. Available from
http://www.ncbi.nlm.nih.gov/books/NBK448202/
PubMed PMID: 28846301.

4: Saul D, Gleitz S, Nguyen HH, Kosinsky RL, Sehmisch S, Hoffmann DB, Wassmann M,
Menger B, Komrakova M. Effect of the lipoxygenase-inhibitors baicalein and
zileuton on the vertebra in ovariectomized rats. Bone. 2017 Aug;101:134-144. doi:
10.1016/j.bone.2017.04.011. Epub 2017 Apr 26. PubMed PMID: 28455215.

5: Sarret C, Pichard S, Afenjar A, Boespflug-Tanguy O. Lack of Long-Term
Neurologic Efficacy of Zileuton in Sjögren-Larsson/’s Syndrome. Neuropediatrics.
2017 Jun;48(3):205-206. doi: 10.1055/s-0037-1601856. Epub 2017 Apr 7. PubMed
PMID: 28388737.

6: Abueid L, Uslu ü, Cumbul A, Velioğlu Öğünç A, Ercan F, Alican İ. Inhibition of
5-lipoxygenase by zileuton in a rat model of myocardial infarction. Anatol J
Cardiol. 2017 Apr;17(4):269-275. doi: 10.14744/AnatolJCardiol.2016.7248. Epub
2016 Nov 10. PubMed PMID: 27849187; PubMed Central PMCID: PMC5469106.

7: Krutetskaya ZI, Milenina LS, Naumova AA, Antonov VG, Nozdrachev AD.
5-Lipoxygenase inhibitor zileuton inhibits Ca(2+)-responses induced by glutoxim
and molixan in macrophages. Dokl Biochem Biophys. 2016 Jul;469(1):302-4. doi:
10.1134/S1607672916040177. Epub 2016 Sep 7. PubMed PMID: 27599517.

8: Tu XK, Zhang HB, Shi SS, Liang RS, Wang CH, Chen CM, Yang WZ. 5-LOX Inhibitor
Zileuton Reduces Inflammatory Reaction and Ischemic Brain Damage Through the
Activation of PI3K/Akt Signaling Pathway. Neurochem Res. 2016
Oct;41(10):2779-2787. Epub 2016 Jul 5. PubMed PMID: 27380038.

9: Magazine R, Shahul HA, Chogtu B, Kamath A. Comparison of oral montelukast with
oral zileuton in acute asthma: A randomized, double-blind, placebo-controlled
study. Lung India. 2016 May-Jun;33(3):281-6. doi: 10.4103/0970-2113.180805.
PubMed PMID: 27185992; PubMed Central PMCID: PMC4857564.

10: Morina N, Boçari G, Iljazi A, Hyseini K, Halac G. Maximum Time of the Effect
of Antileukotriene – Zileuton in Treatment of Patients with Bronchial Asthma.
Acta Inform Med. 2016 Feb;24(1):16-9. doi: 10.5455/aim.2016.24.16-19. Epub 2016
Feb 2. PubMed PMID: 27046942; PubMed Central PMCID: PMC4789724.